Diabetic Foot Ulcers
Conditions
Brief summary
Low intensity shockwaves for treating diabetic foot ulcers (DFUs) have been in evaluation for the past 5 years. Many researchers showed the effectiveness of Low intensity shockwaves of in accelerating the healing rate of non-ischemic chronic DFUs. Wang et al. showed, the use of Low intensity shockwaves on DFUs, significantly improved topical blood flow perfusion rate, increased cell proliferation and cell activity and decreased cell apoptosis. The present study deals with the effect of low intensity shockwaves on DFUs. Shockwave treatment will be done together with the standard conventional treatment for DFUs, compared to a control group who will receive the same conventional standard of care.
Interventions
DEVICEExtracorporeal Shockwave Therapy and debridement
OTHERdebridement and cleaning
Sponsors
Hadassah Medical Organization
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: 1. Chronic non-healing diabetic foot ulcers for more than 2 months. 2. Age 18-80 years 3. Ankle Brachial Index (ABI) ≥0.6 4. Diabetic Foot Ulcer with the long diameter of ≤7cm and a short diameter of ≥1cm 5. The target ulcer is up to Wagner's grade 3 6. Albumin level ≥25g/L 7. Hemoglobin level ≥90g/L 8. Estimated Glomerular Filtration Rate (eGFR) ≥30ml/min/1.73m2 9. The patient agrees to comply with study protocol requirements, including the shockwave procedure, self-care of the ulcer (dressings, orthotics etc.) and all follow-up visit requirements *
Exclusion criteria
1. Pregnancy or lactation 2. ABI \<0.6 3. The long diameter of the target ulcer is \>7cm and the short diameter is \<1cm 4. The target ulcer is of Wagner's grade 4 or above 5. Severe Hypoalbuminemia \<25g/L 6. Severe anemia, Hemoglobin level \<90g/L 7. eGFR \<30ml/min/1.73m2 8. Patients suffering from acute Charcot foot 9. Severe edema of the treated limb 10. Patient with present malignancy or past malignancy in the treated area 11. Systemic chemotherapy/ radiation treatment within the last 6 months 12. Deep vein thrombosis within the last 6 months 13. Any other experimental treatment or participation in other studies \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care. | four weeks |
Outcome results
None listed